PharmAla Delivers MDMA to Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License
Globenewswire·2025-08-07 12:55
TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has completed customs clearance and delivery of over 500 capsules of the company’s LaNeo 40mg MDMA to Merhavim Mental Health Centre of Beer Yaakov, Israel (“Merhavim”). “We believe that this delivery set ...